Prospective Pilot study of Quality of Life in patients with severe late-radiation-toxicity treated by Low hyperbaric-oxigen-therapy.
Hyperbaric chamber
QLQ
Radiotherapy
Toxicity
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
28
12
2022
revised:
24
02
2023
accepted:
20
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
The aim of this study is to assess for the first time the immediate and long term impact on quality-of-life of HBO treatments(HBOT) at 1.45 ATA (Absolute Atmospheric Pressure) Medical Hyperbaric chamber. Patients over 18 years-old, suffering of grade 3 Common Terminology Criteria for Adverse Events (CTCAE) 4.0 radiation induced late toxicity and progressing to standard support therapy were included in this prospective study. HBOT was given daily, sixty minutes per session by a Medical Hyperbaric Chamber Biobarica System at 1.45 ATA at 100% O2. Forty sessions were prescribed for all patients given in 8 weeks. Patients reported outcomes (PROs) was assessed by the QLQ-C30 questionnaire, before starting, in the last week of the treatment, as well as during follow up. Between February-2018/June-2021, 48 patients fulfilled the inclusion criteria. A total of 37 patients (77%) completed the treatment prescribed HBOT sessions. Patients with anal fibrosis (9/37) and brain necrosis (7/37) were the most frequently treated. The most common symptoms were pain (65%) and bleeding (54%). In addition, thirty out of the 37 patients who completed the pre- and post-treatment Patients Reported Outcomes (PROs) assessment also completed the follow up European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire C30 (EORTC-QLQ-C30), and were evaluated in the present study. Mean follow up was 22,10 (6-39) months.The Median score of the EORTC-QLQ-C30, at the end of HBOT and during follow-up, was improved in all assessed domains, except in the cognitive aspect (p = 0.106). HBOT at 1.45 ATA is a feasible and well tolerated treatment, improving long term quality of life in terms of physical function, daily activities and general health subjective state of patients suffering severe late radiation-induced toxicity.
Sections du résumé
Background/purpose
UNASSIGNED
The aim of this study is to assess for the first time the immediate and long term impact on quality-of-life of HBO treatments(HBOT) at 1.45 ATA (Absolute Atmospheric Pressure) Medical Hyperbaric chamber.
Methods
UNASSIGNED
Patients over 18 years-old, suffering of grade 3 Common Terminology Criteria for Adverse Events (CTCAE) 4.0 radiation induced late toxicity and progressing to standard support therapy were included in this prospective study. HBOT was given daily, sixty minutes per session by a Medical Hyperbaric Chamber Biobarica System at 1.45 ATA at 100% O2. Forty sessions were prescribed for all patients given in 8 weeks. Patients reported outcomes (PROs) was assessed by the QLQ-C30 questionnaire, before starting, in the last week of the treatment, as well as during follow up.
Results
UNASSIGNED
Between February-2018/June-2021, 48 patients fulfilled the inclusion criteria. A total of 37 patients (77%) completed the treatment prescribed HBOT sessions. Patients with anal fibrosis (9/37) and brain necrosis (7/37) were the most frequently treated. The most common symptoms were pain (65%) and bleeding (54%). In addition, thirty out of the 37 patients who completed the pre- and post-treatment Patients Reported Outcomes (PROs) assessment also completed the follow up European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire C30 (EORTC-QLQ-C30), and were evaluated in the present study. Mean follow up was 22,10 (6-39) months.The Median score of the EORTC-QLQ-C30, at the end of HBOT and during follow-up, was improved in all assessed domains, except in the cognitive aspect (p = 0.106).
Conclusions
UNASSIGNED
HBOT at 1.45 ATA is a feasible and well tolerated treatment, improving long term quality of life in terms of physical function, daily activities and general health subjective state of patients suffering severe late radiation-induced toxicity.
Identifiants
pubmed: 37066113
doi: 10.1016/j.ctro.2023.100620
pii: S2405-6308(23)00045-9
pmc: PMC10102210
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100620Informations de copyright
©2023PublishedbyElsevierB.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Support Care Cancer. 2009 Dec;17(12):1517-21
pubmed: 19319575
CA Cancer J Clin. 2021 Sep;71(5):437-454
pubmed: 34255347
Int J Technol Assess Health Care. 2008 Spring;24(2):178-83
pubmed: 18400121
Diving Hyperb Med. 2017 Mar;47(1):24-32
pubmed: 28357821
Exp Neurol. 2012 Jun;235(2):517-27
pubmed: 22465460
Adv Wound Care (New Rochelle). 2017 Jun 1;6(6):210-224
pubmed: 28616361
Neurochem Res. 2014 May;39(5):950-60
pubmed: 24682753
Undersea Hyperb Med. 2019 Mar-Apr-May;46(2):101-106
pubmed: 31051054
Undersea Hyperb Med. 2021 Second Quarter;48(2):149-152
pubmed: 33975404
Cancer. 2012 Aug 1;118(15):3860-8
pubmed: 22139864
Clin Otolaryngol Allied Sci. 1996 Oct;21(5):400-3
pubmed: 8932942
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005005
pubmed: 16034961
Eur J Cancer. 2010 Apr;46(6):1033-40
pubmed: 20181476
Radiat Oncol. 2016 Sep 29;11(1):130
pubmed: 27682427
Undersea Hyperb Med. 2020 Second Quarter;47(2):217-228
pubmed: 32574438
Int J Oral Maxillofac Surg. 2008 Mar;37(3):255-9
pubmed: 18262761
Ther Adv Musculoskelet Dis. 2020 Jun 24;12:1759720X20930493
pubmed: 32636943